Reply

Affiliations

¹ Department of General Surgery, Division of Visceral Surgery, Medical University of Vienna, General Hospital Vienna, Vienna, Austria.
² Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, Vienna, Austria.
³ Department of Surgery, Division of Transplantation Surgery, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota, USA.

Comment

David Pereyra et al. Hepatology. 2022 Mar.

. 2022 Mar;75(3):764-765.

doi: 10.1002/hep.32253. Epub 2021 Dec 18.

¹ Department of General Surgery, Division of Visceral Surgery, Medical University of Vienna, General Hospital Vienna, Vienna, Austria.
² Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, Vienna, Austria.
³ Department of Surgery, Division of Transplantation Surgery, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota, USA.

No abstract available

Comment on

Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America.
Ghany MG, King WC, Lisker-Melman M, Lok ASF, Terrault N, Janssen HLA, Khalili M, Chung RT, Lee WM, Lau DTY, Cloherty GA, Sterling RK. Ghany MG, et al. Hepatology. 2021 Nov;74(5):2395-2409. doi: 10.1002/hep.32018. Epub 2021 Sep 9. Hepatology. 2021. PMID: 34133774 Free PMC article. Clinical Trial.
Letter to the editor: The addition of C-reactive protein and von Willebrand factor to Model for End-Stage Liver Disease-Sodium.
Luo MS, Huang GJ. Luo MS, et al. Hepatology. 2022 Mar;75(3):763-764. doi: 10.1002/hep.32252. Epub 2021 Dec 18. Hepatology. 2022. PMID: 34800053 No abstract available.

1. Györi GP, Pereyra D, Rumpf B, Hackl H, Köditz C, Ortmayr G, et al. The von Willebrand factor facilitates model for end-stage liver disease-independent risk stratification on the waiting list for liver transplantation. Hepatology. 2020;72:584-94.
1. Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Scheiner B, et al. Decreasing von Willebrand factor levels upon nonselective beta blocker therapy indicate a decreased risk of further decompensation, acute-on-chronic liver failure, and death. Clin Gastroenterol Hepatol. 2021:S1542-3565(21)00726-6. https://doi.org/10.1016/j.cgh.2021.07.012. [Online ahead of print]
1. Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, et al. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. Aliment Pharmacol Ther. 2018;47:980-8.